Program
State of the Art Lecture
State of the Art Lecture 1
July 12 Sat 8:45-9:15／ROOM A Main Building, B1, Hall Kairaku 1+2
- Chair
- Sheng-Long Ye（Fudan University, Shanghai）
- Speaker
- Jia Fan（Fudan University, Shanghai）
SA-1Precision Diagnosis and Treatment of Hepatocellular Carcinoma
State of the Art Lecture 2
July 12 Sat 13:30-14:00／ROOM A Main Building, B1, Hall Kairaku 1+2
- Chair
- Norihiro Kokudo（National Center for Global Health and Medicine, Tokyo）
- Speaker
- Jian Zhou（Fudan University, Shanghai）
SA-2 A Global Call to Action to Reduce the Burden of Liver Cancer
State of the Art Lecture 3
July 12 Sat 15:20-15:50／ROOM A Main Building, B1, Hall Kairaku 1+2
- Chair
- Jinsil Seong（Yonsei Univ., Seoul）
- Speaker
- Ghassan K Abou-Alfa（Memorial Sloan Kettering Cancer Center, New York）
SA-3Hepatocellular carcinoma: What is the big picture? And are we seeing it?
State of the Art Lecture 4
July 13 Sun 10:15-10:45／ROOM A Main Building, B1, Hall Kairaku 1+2
- Chair
- Masatoshi Kudo（Kindai University, Osaka）
- Speaker
- Takumi Fukumoto（Kobe University, Kobe）
SA-4Current status and Future perspectives of multidisciplinary treatment for advanced HCC in Kobe University
State of the Art Lecture 5
July 13 Sun 14:45-15:15／ROOM A Main Building, B1, Hall Kairaku 1+2
- Chair
- Ann-Lii Cheng（National Taiwan Univ., Taipei）
- Speaker
- Kwang-Hyub Han（Yonsei Univ., Seoul）
SA-5Navigating the optimal management of HCC
State of the Art Lecture 6
July 13 Sun 14:45-15:15／ROOM B Main Building, B1, Hall Kairaku 3
- Chair
- Chiun Hsu（National Taiwan Univ., Taipei）
- Speaker
- Yutaka Suzuki（The University of Tokyo, Kashiwa）
SA-6Towards Multi-Omics Spatial Analysis to Reveal Cancer Heterogeneity
Session 1
Session 1a. Epidemiology and Medical Circumstance for HCC in Asian-Pacific region
July 12 Sat 9:15-10:30／ROOM A Main Building, B1, Hall Kairaku 1+2
- Chair
- Thomas Yau（The Univ. of Hong Kong, Hong Kong）
- Kyung-Suk Suh（Seoul National Univ., Seoul）
- Commentator
- Kazuyoshi Ohkawa（Osaka International Cancer Institute, Osaka）
- Hidekatsu Kuroda（Iwate Medical University, Iwate）
- Speaker
- Lian-Xin Liu（University of Science and Technology of China, Anhui）
- Speaker
- Linda Wong（Univ. of Hawaii, Honolulu）
- Speaker
- Chih-Hung Hsu（National Taiwan Univ., Taipei）
- Speaker
- Joong Won Park（National Cancer Center, Goyang）
- Speaker
- Masayuki Kurosaki（Japanese Red Cross Musashino Hospital, Tokyo）
S1a-1Simultaneous Liver Venous Deprivation Following Hepatic Arterial Chemoembolization before Major Hepatectomy for Hepatocellular Carcinoma to Achieve Hypertrophy Liver Remnant
S1a-2Epidemiology of Liver Cancer in the Pacific Region
S1a-3Management of Hepatocellular Carcinoma in Taiwan ~ the changed and unchanged over the past two decades
S1a-4Changes in Epidemiology and Management of Hepatocellular Carcinoma in South Korea
S1a-5Epidemiology and Medical Circumstances of HCC in Japan
Session 1b. Epidemiology and Basic Science /Translational Research in CCA
July 12 Sat 9:15-10:30／ROOM B Main Building, B1, Hall Kairaku 3
- Chair
- Stephen Chan（The Chinese University of Hong Kong, Hong Kong）
- Yoon Jun Kim（Seoul National Univ., Seoul）
- Commentator
- Hiroshi Imaoka（National Cancer Center Hospital East, Kashiwa）
- Takeshi Terashima（Kanazawa University, Kanazawa）
- Speaker
- Chigusa Morizane（National Cancer Center Hospital, Tokyo）
- Speaker
- Mina Komuta（International University of Health and Welfare, School of Medicine, Narita Hospital, Chiba）
- Speaker
- Qiang Gao（Zhongshan Hospital, Fudan University, Shanghai）
- Speaker
- Hong Jae Chon（CHA University, Seongnam）
S1b-1Epidemiology
S1b-2Cholangiocarcinoma in the Spectrum of Primary Liver Cancers: Diagnostic and Therapeutic Insights from Pathology
S1b-3Gene fusions generate potential therapeutic targets for iCCA
S1b-4Concordance of Circulating Tumor DNA and Tissue Genomic Profiling in Advanced Biliary Tract Cancer
Session 2
Session 2a. Molecular Pathogenesis and Pathology in HCC
July 12 Sat 10:45-12:20／ROOM A Main Building, B1, Hall Kairaku 1+2
- Chair
- Michiie Sakamoto（International University of Health and Welfare, Tokyo）
- Lian-Xin Liu（University of Science and Technology of China, Anhui）
- Commentator
- Shinji Tanaka（Institute of Science Tokyo, Tokyo）
- Jun Akiba（Kurume University, Kurume）
- Speaker
- Young Nyun Park（Yonsei Univ., Seoul）
- Speaker
- Yosuke Togashi（Okayama University, Okayama）
- Speaker
- Irene Ng（The Univ. of Hong Kong, Hong Kong）
- Speaker
- Ying-Hong Shi（Fudan University, Shanghai）
S2a-1Update on the Molecular-Pathological Features of HCC
S2a-2Immune microenvironment in HCC
S2a-3Target Discovery in HCC
S2a-4Delineating the Cellular Ecosystem of Hepatocellular Carcinoma with Microvascular Invasion through Immune-Radiomics Analysis
Session 2b. Locoregional Therapy for CCA
July 12 Sat 10:45-12:20／ROOM B Main Building, B1, Hall Kairaku 3
- Chair
- Su Pin Choo（National Cancer Centre Singapore, Singapore）
- Changhoon Yoo（Univ. of Ulsan, Seoul）
- Commentator
- Michiaki Unno（Tohoku University, Sendai）
- Atsushi Nanashima（Miyazaki University, Miyazaki）
- Speaker
- Masayuki Otsuka（Chiba University, Chiba）
- Speaker
- Tan To Cheung（The Univ. of Hong Kong, Hong Kong）
- Speaker
- Zhao-Chong Zeng（Fudan University, Shanghai）
- Speaker
- William R. Jarnagin（Memorial Sloan Kettering Cancer Center, New York）
S2b-1Current status and challengess in surgical management of intrahepatic cholangiocarcinoma
S2b-2Surgical management of cholangiocarcinoma
S2b-3Radiotherapy for intrahepatic cholangiocarcinoma in the era of immunotherapy
S2b-4Hepatic artery infusion chemotherapy for IHC
Session 3
Session 3a. Surgery and Liver Transplant for HCC
July 12 Sat 14:00-15:15／ROOM A Main Building, B1, Hall Kairaku 1+2
- Chair
- Pierce Chow（National Cancer Centre Singapore, Singapore）
- Zhao-Chong Zeng（Fudan University, Shanghai）
- Commentator
- Susumu Eguchi（Nagasaki University, Nagasaki）
- Tomoharu Yoshizumi（Kyushu University, Fukuoka）
- Speaker
- Kiyoshi Hasegawa（Tokyo University , Tokyo）
- Speaker
- Ming Kuang（Sun Yat-sen University, Guangzhou）
- Speaker
- Linda Wong（Univ. of Hawaii, Honolulu）
- Speaker
- Ying-Hong Shi（Fudan University, Shanghai）
S3a-1Surgical resection combined with systemic therapy for advanced hepatocellular carcinoma
S3a-2State-of-the-Art Surgery for Hepatocellular Carcinoma: Surgeon Scientist’s Viewpoint
S3a-3New Trends in Liver transplant for HCC in the US
S3a-4Conversion therapy for advanced hepatocellular carcinoma to liver resection or transplantation using a combination of systemic and loco-reginal treatments
Session 3b. Systemic Therapy for CCA
July 12 Sat 14:00-15:15／ROOM B Main Building, B1, Hall Kairaku 3
- Chair
- Andrew Zhu（Jiahui International cancer center, Shanghai）
- Chih-Hung Hsu（National Taiwan Univ., Taipei）
- Commentator
- Masafumi Ikeda（National Cancer Center Hospital East, Kashiwa）
- Masashi Kanai（Kansai Medical University Hospital, Osaka）
- Speaker
- Tomoki Ebata（Nagoya University, Nagoya）
- Speaker
- Li-Tzong Chen（National Institute of Cancer Research, National Health Research Institutes (NHRI), Tainan）
- Speaker
- Changhoon Yoo（Univ. of Ulsan, Seoul）
- Speaker
- Do-Youn Oh（Seoul National Univ., Seoul）
S3b-1Adjyuvant chemotherapy for biliary tract cancer
S3b-2Systemic Therapy for Intrahepatic Cholangiocarcinoma: First-line
S3b-3Recent Updates for Second-Line Therapy in Advanced Biliary Tract Cancer (BTC)
S3b-4Systemic therapy for CCA; Ongoing novel clinical trials
Session 4
Session 4a. Locoregional Therapy for HCC
July 12 Sat 17:10-18:30／ROOM A Main Building, B1, Hall Kairaku 1+2
- Chair
- Min-Ke He（Sun Yat-sen University Cancer Center, Guangzhou）
- Do Young Kim（Yonsei Univ., Seoul）
- Commentator
- Kengo Yoshimitsu（Fukuoka University, Fukuoka）
- Takeshi Terashima（Kanazawa University, Kanazawa）
- Speaker
- Ryosuke Tateishi（Tokyo University, Tokyo）
- Speaker
- Yoon Jun Kim（Seoul National Univ., Seoul）
- Speaker
- Ming Shi（Sun Yat-sen University Cancer Center, Guangzhou）
- Speaker
- Jinsil Seong（Yonsei Univ., Seoul）
S4a-1Latest Topics of Ablation Thrapy
S4a-2Latest Topics of TACE/TARE
S4a-3FOLFOX HAIC：The New Regimen of Hepatic Arterial Infusion Chemotherapy for Large Hepatocellular Carcinoma
S4a-4Recent hot topics in radiation therapy; Clinical potential of immunomodulatory effect of radiation by the dose level
Session 4b. Rare Liver Tumors
July 12 Sat 17:10-18:30／ROOM B Main Building, B1, Hall Kairaku 3
- Chair
- Irene Ng（The Univ. of Hong Kong, Hong Kong）
- Young Nyun Park（Yonsei Univ., Seoul）
- Commentator
- Takuji Okusaka（National Cancer Center Hospital, Tokyo）
- Shinichi Aishima（Kyushu University, Fukuoka）
- Speaker
- Tomoyuki Satake（National Cancer Center Hospital East, kashiwa）
- Speaker
- Ghassan K Abou-Alfa（Memorial Sloan Kettering Cancer Center, New York）
- Speaker
- Takamichi Ishii（Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto）
- Speaker
- Satoshi Shiba（National Cancer Center, Tokyo）
- Speaker
- Tomoro Hishiki（Department of Pediatric Surgery, Chiba University, Chiba）
S4b-1Combined Hepatocellular-Cholangiocarcinoma: Diagnosis and Systemic Treatment
S4b-2Fibrolamellar carcinoma
S4b-3Comprehensive Clinicopathological and Whole-Exome Analysis of Cholangiolocarcinoma
S4b-4Epithelioid hemangioendothelioma, an ultra-rare soft tissue sarcoma: recent topics of interest
S4b-5Hepatoblastoma and Pediatric Liver Tumors: Distinct Biology, Global Collaboration, and Evolving Strategies
Session 5
Session 5a. Systemic Therapy for Early-stage HCC
July 13 Sun 8:30-10:00／ROOM A Main Building, B1, Hall Kairaku 1+2
- Chair
- Ming Kuang（Sun Yat-sen University, Guangzhou）
- Qiang Gao（Zhongshan Hospital, Fudan University, Shanghai）
- Commentator
- Akinobu Taketomi（Hokkaido University, Sapporo）
- Makoto Ueno（Kanagawa Cancer Center Research Institute, Kanagawa）
- Speaker
- Pierce Chow（National Cancer Centre Singapore, Singapore）
- Speaker
- Wei Zhang（Tongji Medical College, Wuhan）
- Speaker
- Tomoaki Yoh（Kyoto University, Kyoto）
- Speaker
- Kyung-Suk Suh（Seoul National Univ., Seoul）
- Speaker
- Kaoru Tsuchiya（Japanese Red Cross Musashino Hospital, Tokyo）
S5a-1Adjuvant Therapy after Loco-regional Treatment in Hepatocellular Carcinoma
S5a-2Evolving Landscape and Evidence for Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma
S5a-3Treatment Strategy for Borderline Resectable Hepatocellular Carcinoma
S5a-4Perioperative Treatment of Liver Transplant
S5a-5The Potential Role of Systemic Therapy in Early-Stage Hepatocellular Carcinoma: A Special Clinical Consideration
Session 5b. Debate session
July 13 Sun 8:30-10:00／ROOM B Main Building, B1, Hall Kairaku 3
- Chair
- Tan To Cheung（The Univ. of Hong Kong, Hong Kong）
- Yi-Hsiang Huang（National Yang Ming Chiao Tung University, Taipei）
- Commentator
- Kazuomi Ueshima（Kindai University, Osaka）
- Shinji Itoh（Kyushu University, Fukuoka）
- Speaker
- Masaki Kaibori（Kansai Medical University, Osaka）
- Speaker
- Etsuro Hatano（Kyoto University, Kyoto）
- Speaker
- Junichi Shindoh（Toranomon Hospital , Tokyo）
- Speaker
- Satoshi Kobayashi（Kanagawa Cancer Center, Yokohama）
- Speaker
- Shiro Miyayama（Fukuiken Saiseikai Hospital, Fukui）
- Speaker
- Stephen Chan（The Chinese University of Hong Kong, Hong Kong）
- Speaker
- Yutaka Yasui（Musashino Red Cross Hospital, Tokyo）
- Speaker
- Min-Ke He（Sun Yat-sen University Cancer Center, Guangzhou）
S5b-1Treatment strategy combining ICI chemotherapy and surgery for advanced hepatocellular carcinoma
S5b-2Borderline resectable HCC: Neoadjuvant therapy
S5b-3Conversion possible: resection
S5b-4Conversion possible: Continue systemic therapy
S5b-5Some up-to-7 out hepatocellular carcinomas can be cured by transarterial chemoembolization alone
S5b-6Case 3. Intermediate HCC: TACE+Systemic therapy
S5b-7Case 4. Advanced stage HCC with Vp4: Systemic therapy
S5b-8Advanced stage HCC with Vp4: FOLFOX-HAIC
Session 6
Session 6a. Systemic Therapy for Intermediate-stage HCC
July 13 Sun 10:45-12:15／ROOM A Main Building, B1, Hall Kairaku 1+2
- Chair
- Joong Won Park（National Cancer Center, Goyang）
- Ming Shi（Sun Yat-sen University Cancer Center, Guangzhou）
- Commentator
- Takamichi Murakami（Kobe University, Kobe）
- Teiji Kuzuya（Fujita Health University School of Medicine, Nagoya）
- Speaker
- Do Young Kim（Yonsei Univ., Seoul）
- Speaker
- Yi-Hsiang Huang（National Yang Ming Chiao Tung University, Taipei）
- Speaker
- Masatoshi Kudo（Kindai University, Osaka）
- Speaker
- Shohei Komatsu（Kobe University, Kobe）
- Speaker
- Eisuke Ueshima（Kobe University, Kobe）
S6a-1TACE refractoriness and TACE unsuitability
S6a-2Is systemic therapy alone feasible for intermediate-stage HCC?
S6a-3Combination therapy of TACE with Systemic therapy
S6a-4Utilizing the conversion concept based on disease status following systemic chemotherapy for hepatocellular carcinoma
S6a-5Optimizing Immunotherapy: Radiologist’s Perspective
Session 6b. Hepatology in HCC Management
July 13 Sun 10:45-12:15／ROOM B Main Building, B1, Hall Kairaku 3
- Chair
- Andrew Zhu（Jiahui International cancer center, Shanghai）
- Ryosuke Tateishi（Tokyo University, Tokyo）
- Commentator
- Masato Ozaka（Cancer Institute Hospital of JFCR, Tokyo）
- Tomokazu Kawaoka（Hiroshima University , Hiroshima）
- Speaker
- Hong Jae Chon（CHA University, Seongnam）
- Speaker
- Takahiro Kodama（Osaka University, Osaka）
- Speaker
- Naoko Ohtani（Osaka Metropolitan University, Osaka）
- Speaker
- Taro Shibuki（National Cancer Center Hospital East, Kashiwa）
- Speaker
- Ming-Lung Yu（Kaohsiung Medical University, Kaohsiung）
S6b-1Clinical Feasibility of Circulating Tumor DNA in Advanced Hepatocellular Carcinoma
S6b-2Novel Biomarkers on Immunotherapy Treatment for Unresectable HCC
S6b-3Gut-liver axis-mediated mechanism of liver cancer development: gut microbial components alter liver tumor microenvironment
S6b-4Factors Influencing Immune Checkpoint Inhibitor Efficacy
S6b-5Disparities between viral versus metabolic HCC
Session 7
Session 7a. Systemic Therapy for Advanced-stage HCC
July 13 Sun 13:15-14:45／ROOM A Main Building, B1, Hall Kairaku 1+2
- Chair
- Kwang-Hyub Han（Yonsei Univ., Seoul）
- Sheng-Long Ye（Fudan University, Shanghai）
- Commentator
- Atsushi Hiraoka（Ehime Prefectural Central Hospital, Matsuyama）
- Toshifumi Tada（Kobe University, Kobe）
- Speaker
- Thomas Yau（The Univ. of Hong Kong, Hong Kong）
- Speaker
- Chiun Hsu（National Taiwan Univ., Taipei）
- Speaker
- Sadahisa Ogasawara（Chiba University, Chiba）
- Speaker
- Hyunchul Rhim（Samsung Medical Center, Changwon）
- Speaker
- Ann-Lii Cheng（National Taiwan Univ., Taipei）
S7a-1First-Line Therapy
S7a-2Second-line therapy for unresectable hepatocellular carcinoma (HCC)
S7a-3Evolving strategies for late-line treatment in advanced hepatocellular carcinoma
S7a-4Locoregional Treatment in Advanced HCC: Moving Toward a New Necessity
S7a-5Trends in Drug Development for HCC
Session 7b. Novel strategies for CCA: Others
July 13 Sun 13:15-14:45／ROOM B Main Building, B1, Hall Kairaku 3
- Chair
- Do-Youn Oh（Seoul National Univ., Seoul）
- Masafumi Ikeda（National Cancer Center Hospital East, Kashiwa）
- Commentator
- Hiroshi Imaoka（National Cancer Center Hospital East, Kashiwa）
- Masashi Kanai（Kansai Medical University Hospital, Osaka）
- Speaker
- William R. Jarnagin（Memorial Sloan Kettering Cancer Center, New York）
- Speaker
- Ying-Chun Shen（National Taiwan University Cancer Center, Taipei）
- Speaker
- Su Pin Choo（National Cancer Centre Singapore, Singapore）
- Speaker
- Naoshi Nishida（Kindai University, Osaka）
- Speaker
- Li-Tzong Chen（National Institute of Cancer Research, National Health Research Institutes (NHRI), Tainan）
S7b-1Transplantation for Advanced IHC
S7b-2Noval Targets of Cholangiocarcinoma
S7b-3Molecular Heterogeneity in CCA and predictive biomarkers
S7b-4Immune Landscape of Intrahepatic Cholangiocarcinoma and its Clinical Implication
S7b-5Optimal Dose of Immune Checkpoint Inhibitor -Flat-, Body-weight based-, or Low-dose?
Session 8
Session 8a：Presentations of Selected Abstracts I
July 13 Sun 15:30-16:15／ROOM A Main Building, B1, Hall Kairaku 1+2
- Chair
- Jian Zhou（Fudan University, Shanghai）
- Masayuki Kurosaki（Japanese Red Cross Musashino Hospital, Tokyo）
- Commentator
- Kenji Fukushima（Kobe University, Kobe）
- Takahiro Kodama（Osaka University, Osaka）
- Presenter
- Masaki Omori（Kobe University, Kobe）
- Presenter
- Takashi Nishimura（Hyogo Medical University, Hyogo）
- Presenter
- Pu-Wen Shen（Zhongshan Hospital, Fudan University, Shanghai）
S8a-1Prognostic and predictive value of lymphocyte-to-monocyte transition in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab
S8a-2The usefulness of the non-invasive scoring systems for the hepatocarcinogenesis in patients with MASLD/MASH
S8a-3Tumor Budding Predicts Poor Survival in Hepatocellular Carcinoma Patients Treated with Neoadjuvant/Conversion Therapy: A Cohort Study Using ITBCC Criteria
Session 8b：Presentations of Selected Abstracts II
July 13 Sun 15:30-16:15／ROOM B Main Building, B1, Hall Kairaku 3
- Chair
- Makoto Ueno（Kanagawa Cancer Center Research Institute, Kanagawa）
- Ming-Lung Yu（Kaohsiung Medical University, Kaohsiung）
- Commentator
- Masato Ozaka（Cancer Institute Hospital of JFCR, Tokyo）
- Satoshi Shimizu（Saitama Cancer Center, Saitama）
- Presenter
- Joo-Hyun Park（Korea University Ansan Hospital, Ansan）
- Presenter
- Jaejun Lee（Catholic University of Korea, Seoul）
- Presenter
- Rifaldy Fajar（The Integrated Mathematical, Computational, and Data Science for BioMedicine Research Foundation）
S8b-1Dose-Response Association Between Body Mass Index and the Risk of Cholangiocarcinoma
S8b-2Survival Outcomes of Transarterial Treatment versus Systemic Therapy as Initial Treatment for Hepatocellular Carcinoma with Extrahepatic Metastasis
S8b-3Reconstructing Exosomal Biomechanical Signatures from RNA Profiles to Predict Hepatocellular Carcinoma Progression: A Deep Learning-Based Approach